The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells

Stefania Fiorcari, Wells S. Brown, Bradley W. McIntyre, Zeev Estrov, Rossana Maffei, Susan O'Brien, Mariela Sivina, Julia Hoellenriegel, William G. Wierda, Michael J. Keating, Wei Ding, Neil E. Kay, Brian J. Lannutti, Roberto Marasca, Jan A. Burger

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kaδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior to inducing objective responses in CLL patients. This characteristic activity presumably is due to CLL cell redistribution from tissues into the blood, but the underlying mechanisms are not fully understood. We therefore analyzed idelalisib effects on CLL cell adhesion to endothelial and bone marrow stromal cells (EC, BMSC). We found that idelalisib inhibited CLL cell adhesion to EC and BMSC under static and shear flow conditions. TNFα-induced VCAM-1 (CD106) expression in supporting layers increased CLL cell adhesion and accentuated the inhibitory effect of idelalisib. Co-culture with EC and BMSC also protected CLL from undergoing apoptosis, and this EC- and BMSC-mediated protection was antagonized by idelalisib. Furthermore, we demonstrate that CLL cell adhesion to EC and VLA-4 (CD49d) resulted in the phosphorylation of Akt, which was sensitive to inhibition by idelalisib. These findings demonstrate that idelalisib interferes with integrin-mediated CLL cell adhesion to EC and BMSC, providing a novel mechanism to explain idelalisib-induced redistribution of CLL cells from tissues into the blood.

Original languageEnglish (US)
Article numbere83830
JournalPloS one
Volume8
Issue number12
DOIs
StatePublished - Dec 23 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells'. Together they form a unique fingerprint.

  • Cite this

    Fiorcari, S., Brown, W. S., McIntyre, B. W., Estrov, Z., Maffei, R., O'Brien, S., Sivina, M., Hoellenriegel, J., Wierda, W. G., Keating, M. J., Ding, W., Kay, N. E., Lannutti, B. J., Marasca, R., & Burger, J. A. (2013). The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PloS one, 8(12), [e83830]. https://doi.org/10.1371/journal.pone.0083830